Patients of premature ejaculation (PE), treated with PSD502, a metered dose spray five minutes before sex, could perform 5.5 times longer than those who used a placebo spray.
The finding is based on an evaluation of a combined total of 556 (randomised) and 536 (treated) men with primary PE in the US, Canada and Europe over a three-month period, with more than 23,000 recorded exposures to PSD502.